STAT+: Disappointing tumor responses, more side effects, seen with latest Amgen KRAS combination studies
Combining Amgen’s KRAS-blocking cancer drug Lumakras with other targeted medicines led to higher rates of…
Category: kras
Combining Amgen’s KRAS-blocking cancer drug Lumakras with other targeted medicines led to higher rates of…